Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

393 publications
Année de publication :
Réseaux :

Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous…

Background: Sézary syndrome (SS) and mycosis fungoides (MF), 2 types of cutaneous T-cell lymphoma, cause significant morbidity and adversely affect patients’ quality of life (QoL). The present study assessed the QoL measurement changes in patients receiving mogamulizumab versus vorinostat.

  • Ref: Clin Lymphoma Myeloma Leuk. 2020 Sep 18;S2152-2650(20)30511-5.
  • Auteurs : Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M.
Lire la publication

The emerging potential of cold atmospheric plasma in skin biology.

The maintenance of skin integrity is crucial to ensure the physiological barrier against exogenous compounds, microorganisms and dehydration but also to fulfill social and aesthetic purposes.

  • Ref: Free Radic Biol Med. 2020 Oct 8;161:290-304.
  • Année de publication : 2020
  • Auteurs : Busco G, Robert E, Chettouh-Hammas N, Pouvesle JM, Grillon C.
  • Réseaux : Réseaux: non classé
Lire la publication

Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: A new case report and literature review.

Introduction: BRAF inhibitors±MEK inhibitors can cause panniculitis. Since the initial case described in 2012 by Zimmer et al., some sixty further cases have been reported. Based on a clinical study and a recent and complete review of the literature, we set out in detail the characteristics of panniculitis occurring during BRAF and MEK inhibition therapy as well as the treatment thereof.

  • Ref: Ann Dermatol Venereol. 2020 Sep 15;S0151-9638(20)30317-3.
  • Année de publication : 2020
  • Auteurs : Piroth M, Frénard C, Eugène-Lamer J, Dreno B, Quéreux G
  • Réseaux : Réseaux: non classé
Lire la publication

Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.

Colon cancer develops according to a defined temporal sequence of genetic and epigenetic molecular events that may primarily affect cancer stem cells.

  • Ref: Am J Transl Res. 2020 Sep 15;12(9):5797-5807.
  • Année de publication : 2020
  • Auteurs : Badic B, Durand S, El Khoury F, De La Grange P, Gentien D, Simon B, Le Jossic-Corcos C, Corcos L.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells.

Fibroblastic reticular cells (FRCs) are the specialized lymphoid stromal cells initially identified as triggering T-cell recruitment and dynamic motion in secondary lymphoid organs. Interestingly, FRCs also display antigen presentation capacities and support lymphocyte survival. CXCR5+CD4+ follicular T cells are important players of B-cell maturation and antibody response.

  • Ref: Front Immunol. 2020 Oct 2;11:559866.
  • Année de publication : 2020
  • Auteurs : Misiak J, Jean R, Rodriguez S, Deleurme L, Lamy T, Tarte K, Amé-Thomas P.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature.

Advances in transcriptomics have improved our understanding of leukemic development and helped to enhance the stratification of patients.

  • Ref: Blood Adv. 2020 Oct 27;4(20):5322-5335.
  • Année de publication : 2020
  • Auteurs : Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Récher C, Béné MC, Gouilleux F, Zibara K, Herault O, Mazurier F.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.

Drug repurposing has lately received increasing interest in several diseases especially in cancers, due to its advantages in facilitating the development of new therapeutic strategies, by adopting a cost-friendly approach and avoiding the strict Food and Drug Administration (FDA) regulations.

  • Ref: Curr Med Chem. 2020 Sep 8.
  • Année de publication : 2020
  • Auteurs : Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K.
  • Réseaux : Réseaux: non classé
Lire la publication

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ…

Malignant ovarian germ cell tumors are rare tumors, affecting young women with a generally favorable prognosis.

  • Ref: Gynecol Oncol. 2020 Sep;158(3):666-672.
  • Année de publication : 2020
  • Auteurs : Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T.
  • Réseaux : Réseaux: non classé
Lire la publication